CoolSculpting Side Effects and Safety

CoolSculpting is a device, not a drug, and FDA's records treat it that way.

It is a Class II device cleared through the 510(k) process under the regulation "contact cooling system for aesthetic use" (21 CFR 878.4340) — not an FDA-approved drug or device.

The most recent clearance on file, K233732 for the CoolSculpting Elite System, is dated September 12, 2024.

The technology goes back further: FDA's records show the first authorization was a De Novo grant, DEN090002, dated August 24, 2010, with later clearances adding areas and applicators.

Per Allergan's consumer safety information, the typical side effects after a treatment are temporary:

• redness, swelling, blanching (a short-lived whitening of the skin), bruising and skin inflammation
• firmness, tenderness, stinging, cramping and aching

Sensory changes can outlast the visible ones: itching, skin sensitivity, tingling and numbness can persist up to several weeks after treatment, the same safety information says.

Chin and jawline treatment carries its own note — Allergan says it can cause throat discomfort or a feeling of fullness in the back of the throat.

The peer-reviewed record is, if anything, milder: a 2015 systematic review of 19 cryolipolysis studies found mainly mild, short-term side effects, and no significant effect on blood lipids or liver tests.

That review describes what happened under study conditions, not what any one person will experience.

During treatment, Allergan says you may feel pulling, tugging, mild pinching, intense cold, tingling, stinging, aching and cramping at the treatment site.

The same source says those sensations lessen as the area becomes numb.

Afterward, Allergan's list of typical after-effects includes tenderness, stinging, cramping and aching.

If you have seen CoolSculpting described as painless, note that the maker's own copy does not say that.

Allergan describes recovery as "little to no downtime" and, in the same safety copy, lists pulling, intense cold, stinging and cramping among the sensations.

No source we reviewed puts a number on how much it hurts, so if pain is your main concern, make it the first question at your consultation.

The rare side effect to know by name is paradoxical adipose hyperplasia, or PAH: a visible enlargement of the treated area — what ASPS calls an unexpected increase in the number of fat cells.

Allergan puts rare side effects at 1 to 10 out of 10,000 CoolSculpting treatments (0.01% to 0.1%) and names this enlargement as one of them.

The company says it may develop 2 to 5 months after treatment, will not resolve on its own and may need surgery to correct.

Two details matter: Allergan's figure counts treatments, not patients, and the company's text describes the enlargement without using the term PAH.

The published estimates differ, from one another and from the maker.

The first published report, Jalian et al. in JAMA Dermatology (2014), estimated PAH's incidence at 0.0051% — about 1 in 20,000 treatment cycles — and found no evidence that it resolves on its own.

A 2025 systematic review and meta-analysis (Mah et al., Aesthetic Surgery Journal Open Forum; 28 studies, 13,078 patients) pooled the incidence at 0.22% (95% CI 0.10–0.47%), which is 1 in 455 patients, judged the evidence low-certainty, and concluded PAH appears more common than manufacturer reports.

The meta-analysis counts per patient and Allergan counts per treatment, so the two figures are not directly comparable.

Even who is more at risk is contested.

ASPS says PAH occurs rarely, in less than 1 percent of patients, and describes it as three times more likely in men than women and seen more in people of Hispanic or Latino descent.

The 2025 meta-analysis, by contrast, found sex-based differences that were not statistically significant.

It did count 10 of 29 reported PAH cases (34.5%) involving the CoolCore applicator, but judged the data too sparse for a device-level analysis.

The honest summary is a range, not a number: published estimates run from 0.0051% (2014) to 0.22% per patient (2025), and the manufacturer's own figure for rare side effects is 0.01% to 0.1% of treatments.

If a provider quotes you a single PAH rate, ask which source it comes from.

PAH is not the only unhelpful outcome ASPS names: it also lists surface irregularities, asymmetry and not getting the hoped-for result among the risks of cryolipolysis.

Allergan's safety information is specific: people with cryoglobulinemia, cold agglutinin disease or paroxysmal cold hemoglobinuria should not be treated with CoolSculpting or CoolSculpting Elite.

The same page asks patients to tell their doctor about pregnancy, recent surgery, a pre-existing hernia, or known sensitivities or allergies before treatment.

ASPS keeps its own list for cryolipolysis: it names cryoglobulinemia, cold urticaria and paroxysmal cold hemoglobinuria and says people with these conditions should not have the procedure.

Where Allergan names cold agglutinin disease, ASPS names cold urticaria — the lists overlap but are not identical, which is a reason to give your full medical history at the consultation rather than screen yourself against one of them.

ASPS adds two more filters: people with loose skin or poor tone may not be suitable candidates, and people who are pregnant or breastfeeding should not have nonsurgical fat reduction procedures, cryolipolysis included.

Reading this page is not a screening.

Whether the treatment is appropriate for your history and your goals is a judgment for a licensed provider who can examine you.

The device and the operator both shape the experience, so make both explicit before you book.

Ask which system will be used, who will run it, and how they trained on it.

FDA's records run from the 2010 De Novo grant through later clearances for added areas and applicators, the most recent being K233732 for the CoolSculpting Elite System, dated September 12, 2024 — so a clinic should be able to name the system and applicator it uses.

Use the consultation to work through this page: disclose cold-related conditions, hernias, recent surgery and pregnancy, and ask the provider to walk you through PAH — what it is, how they would recognize it, and how it would be corrected if it happened.

For the other half of the decision — what the treatment is cleared to treat, what the studies show and how it is priced — start with the CoolSculpting guide, then compare clinics.